Trial reportCritical care science2026
A secondary analysis of the SODa-BIC randomized clinical trial using multiple hierarchical composite outcomes.
Trial report in Critical care science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Sodium Bicarbonate for Metabolic Acidosis in the ICU (SODa-BIC) trial assessed the effect of sodium bicarbonate on Major Adverse Kidney Events at 30 days (MAKE30) in critically ill patients with metabolic acidosis. Although the trial demonstrated no significant difference in the primary outcome, the individual components showed differing magnitudes and directions of effect; we undertook an exploratory analysis of the SODa-BIC trial using different hierarchical outcomes to better understand potential treatment effects of sodium bicarbonate.
methodsPost-hoc analysis of the SODa-BIC trial. All patients included in the SODa-BIC trial were eligible. The primary outcome was a win ratio analysis with a hierarchy consisting of death, requirement for renal replacement therapy, persistent renal dysfunction, and hospital length of stay. Several sensitivity and subgroup analyses were conducted.
resultsThe primary analysis resulted in 59,250 pairs from 488 patients. Consistent with the SODa-BIC analysis, there was no overall evidence of a treatment effect of sodium bicarbonate, with a win ratio of 0.97 (95%CI 0.79 - 1.19) and a Desirability of Outcome Ranking probability of 0.49 (95%CI 0.45 - 0.54). A majority of pairwise comparisons were resolved by mortality and hospital length of stay. Evidence of significant treatment effect modification was observed across subgroups defined by acute kidney injury and severity of acidemia.
conclusionIn this post-hoc analysis of the SODa-BIC trial, the use of hierarchical composite outcomes did not alter the neutral overall interpretation of the original trial. However, this analysis provides additional insight into the relative contribution of individual components of the primary outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.